News
Filing of patent infringement suit by Ono Pharma against AstraZeneca K.K. relating to Imfinzi.
Ono Pharmaceutical Co., Ltd. announced that it has filed a lawsuit for an injunction and damages (value of the subject matter of the suit is about 32 billion yen) against patent infringement, based on the patent on the anti-PD-L1 antibody owned by Ono (JP5885764; JP6258428), to the Tokyo District Court on February 28 against AstraZeneca K.K., which has been marketing Imfinzi (durvalumab).
Considering that the treatment is related to the life-saving of patients, Ono will not ask for a sales injunction of Imfinzi in this lawsuit, if Ono would make an agreement with AstraZeneca K.K. which will pay an appropriate consideration including royalties even outside the proceedings.
Condition: Non Small Cell Lung Cancer
Type: drug